|
⚲
|
| Keyboard |
| Suvretta Capital Management LLC
✚
|
|
|---|---|
| CRD # | 165153 |
| SEC # | 801-79962 |
| CIK # | 0001569064 |
| AUM | 7,866.7 M (2026-03-19) |
| Employees | 23 (52% Investors, 0% Brokers) |
| Phone | 212-702-5200 |
| Address | 540 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Arcutis Biotherapeutics Inc | 0.3 | ||
| Veradermics Inc | 0.3 | ||
| Marika Inc | 0.1 | ||
| Legend Biotech Corp | 0.1 | ||
| Benitec Biopharma Inc | 0.1 | ||
| Nile Therapeutics Inc | 0.1 | ||
| Immatics NV | 0.1 | ||
| Arcus Biosciences Inc | 0.1 | ||
| Psivida Corp | 0.1 | ||
| Arrivent Biopharma Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Averill Madison Master Fund Ltd | [2023-02-09] | 45.4 M | 807.7 M |
| Filed 2025-11-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Averill Opportunities Offshore Fund I LP | [2021-03-29] | 14.9 M | 0.1 M |
| Filed 2021-01-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Averill Master Fund Ltd | [2020-03-26] | 594.4 M | 4,308.6 M |
| Filed 2026-03-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Suvretta Long Master Fund Ltd | [2017-01-18] | 42.0 M | 2.3 M |
| Filed 2022-06-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Suvretta Master Fund Ltd | [2012-09-28] | 619.2 M | 2,702.2 M |
| Filed 2025-06-13 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 7.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 10 | 7.9 |
| By Discretionary | ||
| Discretionary | 10 | 7.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 10 | 7.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 7.9 | |
| United States Persons | 0.0 | |
| Total | 10 | 7.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| William Shaw | Director | 93 | 23 | |
| Tammy Seymour | Director | 48 | 20 | |
| Sherri Fleming | Director | 53 | 12 | |
| Glenn Mitchell | Director | 32 | 12 | |
| T Mitchell | Director | 29 | 11 | |
| Suvretta Capital Management LLC | Executive Officer | 8 | 2 | |
| Aaron Cowen | Director, Executive Officer | 5 | 2 | |
| Averill Opportunities LLC | Executive Officer | 2 | 2 | |
| Averill GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001569064] | |
| 3 | [0001569064] | |
| 4 | [0001569064] | |
| SC 13D | [0001569064] | |
| SC 13G | [0001569064] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300B4WZUAJTMV4E82 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Averill Master Fund Ltd | |
| Averill Madison Master Fund Ltd | |
| Suvretta Capital Management LLC | |
| Veradermics Inc | |
| Cowen Aaron | |
| Benitec Biopharma Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-06 | Buy | 19,338 | $36.55 | 706,804 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-06 | Buy | 11,183 | $35.97 | 402,253 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 16,563 | $39.80 | 659,207 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 17,835 | $38.67 | 689,679 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 38,771 | $37.63 | 1,458,953 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 19,199 | $36.93 | 709,019 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 3,832 | $36.07 | 138,220 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 25,908 | $38.09 | 986,836 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 53,344 | $37.11 | 1,979,596 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 3,178 | $38.90 | 123,624 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 10,676 | $34.74 | 370,884 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 10,004 | $34.25 | 342,637 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 14,659 | $36.27 | 531,682 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 4,453 | $38.09 | 169,615 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 9,168 | $37.11 | 340,224 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 2,519 | $36.27 | 91,364 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 1,835 | $34.74 | 63,748 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 1,720 | $34.25 | 58,910 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 18,489 | $38.90 | 719,222 |
|
Benitec Biopharma Inc BNTC
Common stock, par value $0.0001 per share
|
2025-12-29 | Buy | 11,587 | $13.44 | 155,729 |
| showing 20 of 59 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Ironwood Capital Management Corp
✚
|
CA | 8,225.8 M |
|
Wincoram Asset Management LLC
✚
|
TX | 8,186.1 M |
|
Starboard Value LP
✚
|
NY | 8,151.9 M |
|
Overlook Investments Limited
✚
|
8,092.8 M | |
|
Overlook Investments LP
✚
|
8,092.8 M | |
|
Context Capital Management LLC
✚
|
CA | 8,008.2 M |
|
Polunin Capital Partners Limited
✚
|
7,959.6 M | |
|
LoanCore Capital Credit Advisor LLC
✚
|
CT | 7,922.4 M |
|
Kensico Capital Management Corp
✚
|
CT | 7,876.6 M |
|
Sessa Capital IM LP
✚
|
NY | 7,524.2 M |